STOCK TITAN

Sagimet Biosciences Inc. Series A - $SGMT STOCK NEWS

Welcome to our dedicated page for Sagimet Biosciences Series A news (Ticker: $SGMT), a resource for investors and traders seeking the latest updates and insights on Sagimet Biosciences Series A stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Sagimet Biosciences Series A's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Sagimet Biosciences Series A's position in the market.

Rhea-AI Summary
Sagimet Biosciences Inc. (SGMT) to participate in the First Annual Goldman Sachs Catalyst Clinic, with a virtual fireside chat on December 6, 2023, to discuss its novel FASN inhibitors targeting dysfunctional metabolic pathways.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.12%
Tags
conferences
-
Rhea-AI Summary
Sagimet Biosciences Inc. (SGMT) will present preclinical data at the 7th Obesity and NASH Drug Development Summit on November 28, 2023, in Boston. The data demonstrates the effectiveness of their FASN inhibitor in reducing liver fibrosis in a preclinical mouse model of NASH, supporting further clinical evaluation. Sagimet remains focused on advancing denifanstat as a potential monotherapy and is on track to report topline results of their FASCINATE-2 Phase 2b clinical trial in the first quarter of next year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.56%
Tags
-
Rhea-AI Summary
Sagimet Biosciences Inc. (SGMT) to participate in the 35th Annual Piper Sandler Healthcare Conference. CEO and CMO to hold fireside chat and one-on-one meetings with investors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.58%
Tags
conferences
Rhea-AI Summary
Sagimet Biosciences Inc. (SGMT) reported financial results for Q3 2023, with key updates on clinical trials for denifanstat in NASH, oncology, and acne. The company anticipates topline week 52 liver biopsy results from the Phase 2b FASCINATE-2 trial in Q1 2024. Financially, Sagimet's cash and cash equivalents were $101.8 million, with revenues of $2.0 million for Q3 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.73%
Tags
-
Rhea-AI Summary
Sagimet Biosciences Inc. (Nasdaq: SGMT) announced positive results from a preclinical study detailing the combination treatment of a FASN inhibitor with semaglutide for NASH, showing significant improvement in liver fibrosis. The company is on track to report Phase 2b clinical trial results, including liver biopsy, in Q1 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.68%
Tags
-
Rhea-AI Summary
Sagimet Biosciences announces acceptance of two abstracts at AASLD conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.41%
Tags
none
Rhea-AI Summary
Sagimet Biosciences to participate in fireside chat and investor meetings at NASH Investor Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-17.06%
Tags
conferences
-
Rhea-AI Summary
Sagimet Biosciences' license partner, Ascletis, has enrolled 120 patients in its Phase 3 clinical trial for denifanstat combined with bevacizumab for recurrent glioblastoma, which is expected to provide sufficient events for an interim analysis of progression-free survival.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.13%
Tags
-
Rhea-AI Summary
Sagimet Biosciences completes upsized IPO raising $96.4M in gross proceeds. Positive data from Phase 2b trial shows denifanstat well-tolerated and meeting liver fat response endpoint. Leadership changes implemented. Financial results show cash balance of $18.5M as of June 30, 2023, with net proceeds of $86.2M from IPO.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.73%
Tags
Rhea-AI Summary
Sagimet Biosciences Inc. has announced the closing of the sale of an additional 714,272 shares of Series A common stock at the initial public offering price of $16.00 per share. After the exercise of the underwriters' option, Sagimet has issued a total of 6,026,772 Series A common stock, raising approximately $96.4 million in gross proceeds.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.71%
Tags
Sagimet Biosciences Inc. Series A

Nasdaq:SGMT

SGMT Rankings

SGMT Stock Data

136.59M
19.51M
13.48%
47.29%
7.36%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United States of America
SAN MATEO